The SnapChip™ for a Precise Chip-to-Chip Transfer of Nanodroplets

Wednesday, 19 June 2019 at 16:45

Add to Calendar ▼2019-06-19 16:45:002019-06-19 17:45:00Europe/LondonThe SnapChip™ for a Precise Chip-to-Chip Transfer of NanodropletsPoint-of-Care, Biosensors and Mobile Diagnostics Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Multiplexed sandwich immunoassays are a powerful technique to measure multiple protein concentrations simultaneously. However, multiplexed assays are prone to cross reactivity effects and can generate false positive signals due to a lack of antibody specificity and selectivity. This is a known weakness of multiplexed assays that is mitigated by months of assay optimization and validation.

Parallex BioAssays replaced the “detection soup” of antibodies by an array of nanodroplets and offers a new CHIP-to-CHIP approach to deliver the detection antibodies precisely to their cognate spots of capture antibodies. As a result, a cross-reaction free chip consisting of an assembly of parallelized assays, physically isolated from each other. The advantages include the possibility to mix-and-match assays and create unique combinations, such as isoforms and phospho-specific antibodies side-by-side. This makes our approach to cell signaling studies (e.g. Akt activation pathway) a rapid and easy alternative to performing dozens of western blots.

The SnapChip™ represents a new format of liquid handling platforms. Beyond exclusive immunoassays, it creates the opportunity to miniaturize and multiplex enzyme activity and cell-based assays in nano-compartments. Current and future applications will be discussed.

Sebastien Bergeron, Founder and CEO, Parallex BioAssays Inc.

Sebastien Bergeron

Sebastien Bergeron is the founder and CEO of Parallex BioAssays. He completed a Ph.D. in physiology and endocrinology, with a focus on type II diabetes. As a postdoctoral fellow in the Biomedical Engineering department at McGill University, he developed a strong interest in microfluidics and immunoassay miniaturization. He drove the development of a new microarray format, called the SnapChip™. This cross-reaction-free platform offers high quality results while permitting rapid, flexible and customized multiplexed immunoassay development. In 2015, Sebastien founded Parallex BioAssays to make this technology available to the scientific community.